Tenderwize
Retour à la recherche

Open-house rebate agreements for Lopinavir/Ritonavir

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 406 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Lopinavir und Ritonavir, ATC J05AR10

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

For the first contract start, documents must be received by 31.12.2025; the notice says receipt by the buyer is decisiv...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Nov 30, 2027

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Lopinavir and Ritonavir (ATC J05AR10).
  • Supply/contracting scope is limited to medicines that are authorised and marketable in Germany.
Afficher le résumé complet

This is a non-exclusive open-house supply arrangement for pharmaceutical products containing Lopinavir and Ritonavir (ATC J05AR10) offered by AOK Rheinland-Pfalz/Saarland. The contract period runs from 01.02.2026 to 31.01.2028, with monthly entry possible during the 24-month window. The notice explicitly excludes medicines listed as children’s medicines under the BfArM list (§ 35(5a) SGB V). No contract value is stated. Submission is not electronic-only: paper originals or electronically signed documents by email are allowed, and the notice says the first award/contract conclusion can occur no earlier than 10 days after publication.

Risques

For the first contract start, documents must be received by 31.12.2025; the notice says receipt by the buyer is decisiv...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Medicines must be authorised and marketable in Germany.

Eligibility

  • Only pharmaceutical companies are eligible to become contract partners.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided with specified product and authorisation details.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreements for Lopinavir/Ritonavir

Single open-house lot for non-exclusive rebate agreements covering medicines with the active substance Lopinavir and Ritonavir (ATC J05AR10). The buyer states that all interested pharmaceutical companies may join on equal terms, without individual negotiation or selection. Children’s medicines listed in the BfArM list are excluded. Contract duration is up to 24 months, starting no earlier than 01.02.2026, with monthly entry possible. The lot information comes from structured data and notice text.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 30, 2027

Détails de la procédure

Date de publication
09 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
819132-2025

Documents (1)

Appels d'offres similaires